Analysis of medication rule of master of national physician Zhang Daning in the treatment of chronic kidney disease based on data mining
LI Hucai LIN Junjie HE Zhiren WANG Lixin#br#
Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510000, China
Abstract：Objective To analyze and summarize the medication rule of master of national physician Zhang Daning in the treatment of chronic kidney disease based on data mining. Methods Medical records of Professor Zhang Daning’s diagnosis and treatment of chronic kidney disease from January 2020 to December 2020 were selected from the medical records database of famous doctors’ studio of Zhang Daning of Guangdong Provincial Hospital of Chinese Medicine. Descriptive analysis and cluster analysis were performed for high-frequency drugs in medical cases (frequency≥20%). The association rules analysis were conducted with Apriori algorithm. Results A total of 143 medical cases, 143 prescriptions, and 138 single Chinese herbs were included. The top five Chinese herbs were Astragali Radix, Salviae Miltiorrhizae Radix Et Rhizoma, Chuanxiong Rhizoma, Smilacis Glabrae Rhizoma, and Dendrobii Caulis. The top five high-frequency herbs in frequency were promoting blood circulation and removing stasis, tonifying deficiency, unblocking fu-organs to remove turbidity, removing dampness, and astringent herbs. Herbs were distinguished by four nature of drugs, 12 herbs were warm and slightly warm, 9 herbs were flat, 5 herbs were cold and slightly cold. Herbs were distinguished by five flavors, 16 herbs were sweet, 14 herbs were bitter, and 9 herbs were pungent. Herbs were distinguished by channel tropism, 20 herbs belonged to spleen channel, 13 herbs belonged to liver channel, 12 herbs belonged to kidney channel. High-frequency drugs were divided into 7 clusters by cluster analysis. After the analysis of association rules, 33 related rules were obtained. Conclusion Professor Zhang Daning’s treatment of chronic kidney disease focuses on tonifying deficiency, promoting blood circulation and removing stasis, and unblocking fu-organs to remove turbidity. The self-made prescription Yinchen Shixiao Powder is the basic prescription, which could provide reference for traditional Chinese medicine treatment of chronic kidney disease.
李虎才 林俊杰 何志仁 王立新. 基于数据挖掘的国医大师张大宁治疗慢性肾脏病用药规律分析[J]. 中国医药导报, 2022, 19(14): 133-137.
LI Hucai LIN Junjie HE Zhiren WANG Lixin. Analysis of medication rule of master of national physician Zhang Daning in the treatment of chronic kidney disease based on data mining. 中国医药导报, 2022, 19(14): 133-137.
[1] Ojo A. Addressing the global burden of chronic kidney disease through clinical and translational research [J]. Trans Am Clin Climatol Assoc，2014，125：229-243.
[2] Saran R，Robinson B，Abbott K，et al. US Renal Data System 2018 Annual Data Report：Epidemiology of Kidney Disease in the United States [J]. Am J Kidney Dis，2019， 73（3 Suppl 1）：A7-A8.
[3] Zhang L，Wang F，Wang L，et al. Prevalence of chronic kidney disease in China：a cross-sectional survey [J]. Lancet，2012，379（9818）：815-822.
[4] Liang Z，Wang W，Yang C，et al. Residential greenness and prevalence of chronic kidney disease：Findings from the China National Survey of Chronic Kidney Disease [J]. Sci Total Environ，2022，806（Pt 2）：150628.
[5] Li G，Huang J，Wang J，et al. Long-Term Exposure to Ambient PM（2.5）and Increased Risk of CKD Prevalence in China [J]. J Am Soc Nephrol，2021，32（2）：448-458.
[6] Blum MF，Surapaneni A，Stewart JD，et al. Particulate Matter and Albuminuria，Glomerular Filtration Rate，and Incident CKD [J]. Clin J Am Soc Nephrol，2020，15（3）：311-319.
[7] Yang C，Wang H，Zhao X，et al. CKD in China：Evolving Spectrum and Public Health Implications [J]. Am J Kidney Dis，2020，76（2）：258-264.
[8] GBD Chronic Kidney Disease Collaboration. Global，regional，and national burden of chronic kidney disease，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet，2020，395（10225）：709-733.
[9] Lv JC，Zhang LX. Prevalence and Disease Burden of Chronic Kidney Disease [J]. Adv Exp Med Biol，2019，1165：3-15.
[10] Tomson CRV，Cheung AK，Mann JFE，et al. Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis：Synopsis of the 2021 KDIGO Clinical Practice Guideline [J]. Ann Intern Med，2021，174（9）：1270-1281.
[11] 高学敏.中药学[M].9版.北京：中国中医药出版社，2017.
[12] Jhang K，Chang M，Lo T，et al. Using The Apriori Algorithm To Classify The Care Needs Of Patients With Different Types Of Dementia [J]. Patient Prefer Adherence，2019，13（6）：1899-1912.
[13] 贾鸿扬，徐英.张大宁教授应用茵陈失笑散治疗慢性肾功能衰竭验案[J].西部中医药，2016，29（3）：68-70.
[14] 杨茹茜，王雪.黄芪及其制剂基于信号通路机制抗肾纤维化的研究概况[J].中华中医药杂志，2020，35（6）：3023-3026.
[15] 张善宝，王小玉，漆映辉，等.黄芪注射液对DKD（CKD3期）患者氧化应激状态、胰岛素抵抗及肾功能的影响[J].中国中西医结合肾病杂志，2020，21（6）：497-500.
[16] Zhang，Shergis J，Yang L，et al. Astragalus membranaceus（Huang Qi） as adjunctive therapy for diabetic kidney disease：An updated systematic review and meta-analysis [J]. J Ethnopharmacol，2019，35（6）：239-243.
[17] Alshinnawy AS，El-Sayed WM，Taha AM，et al. Astragalus membranaceus and Punica granatum alleviate infertility and kidney dysfunction induced by aging in male rats [J]. Turk J Biol，2020，44（4）：166-175.
[18] 刘正平，曹钋，钟剑，等.基于网络药理学探究黄芪-党参药对治疗糖尿病肾病的作用机制[J].中国医药导报，2021，18（34）：121-125，197.
[19] 郑雷，陈翔，尹博炜，等.洋川芎内酯A对单侧输尿管梗阻大鼠肾间质纤维化的作用及机制研究[J].中国中西医结合外科杂志，2020，26（2）：237-242.
[20] 单福军，孙铁忠，齐卡，等.川芎素注射液治疗慢性肾功能衰竭482例[J].现代中西医结合杂志，2004，10（23）：3139-3140.
[21] 张晓娟，张燕丽，左冬冬.川芎的化学成分和药理作用研究进展[J].中医药信息，2020，37（6）：128-133.
[22] 翟吴剑文，张利丹，谢雁鸣，等.真实世界中丹参川芎嗪注射液治疗肾功能损害人群的临床特征研究[J].中药药理与临床，2021，37（1）：188-193.
[23] 陈程，李均.丹参及其有效成分对肾纤维化的影响作用[J].中国中西医结合肾病杂志，2020，21（12）：1119-1121.
[24] 孙成博，孙波，刘春禹，等.茵陈提取物对糖尿病大鼠肾组织中miRNAs表达谱的影响及其肾脏保护作用[J].吉林大学学报（医学版），2018，44（3）：493-498，695.
[25] 张淑霞，霍文博，苏莹，等.茵陈提取物对糖尿病大鼠肾组织中PTEN蛋白表达的影响及其肾脏保护作用[J].吉林大学学报（医学版），2019，45（4）：779-783，982.
[26] 赵怡蕊，陈曦，牛肖媛，等.国医大师张大宁教授巧用炭剂治肾病[J].世界中医药，2015，10（12）：1906-1908.
[27] 樊威伟，车树强，徐英，等.茵陈失笑散延缓慢性肾功能不全进程的临床研究[J].天津中医药，2010，27（2）：103-104.
京公网安备 11010502046598号